Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Share-based Compensation (2021 - 2025)

Prime Medicine (PRME) has disclosed Share-based Compensation for 5 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 24.0% year-over-year to $4.5 million, compared with a TTM value of $29.3 million through Dec 2025, up 12.28%, and an annual FY2025 reading of $29.3 million, up 12.28% over the prior year.
  • Share-based Compensation was $4.5 million for Q4 2025 at Prime Medicine, down from $12.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.7 million in Q3 2025 and bottomed at $1.1 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $4.5 million, with a median of $4.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 209.88% in 2024, then fell 24.0% in 2025.
  • Year by year, Share-based Compensation stood at $1.1 million in 2021, then surged by 132.52% to $2.6 million in 2022, then surged by 72.07% to $4.4 million in 2023, then skyrocketed by 34.14% to $5.9 million in 2024, then fell by 24.0% to $4.5 million in 2025.
  • Business Quant data shows Share-based Compensation for PRME at $4.5 million in Q4 2025, $12.7 million in Q3 2025, and $6.3 million in Q2 2025.